...
首页> 外文期刊>Biochemistry >Bupropion Binds to Two Sites in the Torpedo Nicotinic Acetylcholine Receptor Transmembrane Domain: A Photoaffinity Labeling Study with the Bupropion Analogue [~(125)I]-SADU-3-72
【24h】

Bupropion Binds to Two Sites in the Torpedo Nicotinic Acetylcholine Receptor Transmembrane Domain: A Photoaffinity Labeling Study with the Bupropion Analogue [~(125)I]-SADU-3-72

机译:安非他酮绑定到鱼雷烟碱乙酰胆碱受体跨膜域中的两个站点:与安非他酮类似物[〜(125)I] -SADU-3-72的光亲和标记研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Bupropion, a clinically used antidepressant and smoking-cessation drug, acts as a noncompetitive antagonist of nicotinic acetylcho-line receptors (nAChRs). To identify its binding site(s) in nAChRs, we developed a photoreactive bupropion analogue, (±)-2-(N-tert-butylamino)-3'-[~(125)I]-iodo-4'-azidopropiophenone (SADU-3-72). Based on inhibition of [~(125)I]SADU-3-72 binding, SADU-3-72 binds with high affinity (IC_(50) = 0.8 μM) to the Torpedo nAChR in the resting (closed channel) state and in the agonist-induced desensitized state, and bupropion binds to that site with 3-fold higher affinity in the desensitized (IC_(50) = 1.2 μM) than in the resting state. Photolabeling of Torpedo nAChRs with [~(125)I]SADU-3-72 followed by limited in-gel digestion of nAChR subunits with endoproteinase Glu-C established the presence of [~(125)I]SADU-3-72 photoincorporation within nAChR subunit fragments containing Ml-M2-M3 helices (αV8-20K,β8-22/23K, and γV8-24K) or Ml-M2 helices (5V8-14). Photolabeling within βVS-22/23K, γV8-24K, and δV8-14 was reduced in the desensitized state and inhibited by ion channel blockers selective for the resting (tetracaine) or desensitized (thienycyclohexylpiperidine (TCP)) state, and this pharmacologically specific photolabeling was localized to the M2-9 leucine ring (δLeu~(265), βLeu~(257)) within the ion channel. In contrast, photolabeling within the αV8-20K was enhanced in the desensitized state and not inhibited by TCP but was inhibited by bupropion. This agonist-enhanced photolabeling was localized to αTyr~(213) in αMl. These results establish the presence of two distinct bupropion binding sites within the Torpedo nAChR transmembrane domain: a high affinity site at the middle (M2-9) of the ion channel and a second site near the extracellular end of αM1 within a previously described halothane (general anesthetic) binding pocket.
机译:安非他酮是临床上使用的抗抑郁药和戒烟药,可作为烟碱乙酰胆碱受体(nAChRs)的非竞争性拮抗剂。为了鉴定其在nAChRs中的结合位点,我们开发了一种光反应性安非他酮类似物(±)-2-(N-叔丁基氨基)-3'-[〜(125)I]-碘-4'-叠氮苯丙酮( SADU-3-72)。基于[〜(125)I] SADU-3-72结合的抑制,SADU-3-72在静止(封闭通道)状态和静止状态下以高亲和力(IC_(50)= 0.8μM)与鱼雷nAChR结合。激动剂诱导的脱敏状态,安非他酮在脱敏状态下以3倍的亲和力与该位点结合(IC_(50)= 1.2μM),比静止状态高3倍。用[〜(125)I] SADU-3-72对鱼雷nAChRs进行光标记,然后用内切蛋白酶Glu-C对nAChR亚基进行有限的凝胶内消化,确定了[〜(125)I] SADU-3-72光掺入的存在包含M1-M2-M3螺旋(αV8-20K,β8-22/ 23K和γV8-24K)或M1-M2螺旋(5V8-14)的nAChR亚基片段。 βVS-22/ 23K,γV8-24K和δV8-14内的光标记在脱敏状态下减少,并受到对静止(丁卡因)或脱敏(噻吩基环己基哌啶(TCP))选择性的离子通道阻滞剂的抑制,并且这种药理学特异性光标记离子通道内的M1-9定位于M2-9亮氨酸环(δLeu〜(265),βLeu〜(257))。相反,αV8-20K内的光标记在脱敏状态下增强,不受TCP抑制,但被安非他酮抑制。该激动剂增强的光标记定位于αM1中的αTyr_(213)。这些结果确定了Torpedo nAChR跨膜结构域中存在两个不同的安非他酮结合位点:离子通道中间(M2-9)的高亲和力位点和先前描述的氟烷中αM1胞外端附近的第二个位点(全身麻醉药)的装袋处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号